NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date and time:** Wednesday 4 May 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Richard Nicholas (Chair – Topic1) Present for all items
2. Professor Stephen O’Brien (Chair Topic 2) Present for all items
3. Iftab Akram Present for all items
4. Dr Alex Cale Items 1 to 4.3.2
5. Michael Chambers Present for all items
6. Dr Prithwiraj Das Present for all items
7. Dr Rob Forsyth Present for all items
8. Dr Natalie Hallas Present for all items
9. John Hampson Present for all items
10. Dr Nigel Langford Present for all items
11. Iain McGowan Present for all items
12. Kirandip Moyo Present for all items
13. Dr Mudasar Mushtaq Items 1 to 4.3.2
14. Stella O’Brien Present for all items
15. Professor Andrew Renehan Present for all items
16. Professor Matthew Stevenson Present for all items
17. Professor Paul Tappenden Present for all items

NICE staff present

Linda Landells, Associate Director Items 1 to 4.3.2

Ross Dent, Associate Director Items 5 to 5.2.2

Kate Moore, Project Manager Present for all items

Louise Jafferally, Project Manager Present for all items

Alex Filby, Heath Technology Assessment Adviser Items 1 to 4.3.2

Charlie Hewitt, Heath Technology Assessment Adviser Items 5 to 5.2.2

Nigel Gumbleton, Heath Technology Assessment Analyst Items 1 to 4.3.2

Kirsty Pitt, Heath Technology Assessment Analyst Items 5 to 5.2.2

Dilan Savani, Heath Technology Assessment Analyst Items 1 to 4.3.2

Benjamin Gregory, Business Analyst, RIA Present for all items

Claire Hawksworth, Technical Analyst, Managed Access Items 1 to 4.3.2

Emily Eaton-Turner, Technical Analyst, Commercial Risk Assessment, Items 5 to 5.2.2

Olivia Havercroft, Senior Medical Editor Items 1 to 4.1.3

Ruth Melville, Senior Medical Editor Items 5 to 5.2.2

Ella Fitzpatrick, Public Involvement Adviser, PIP Items 1 to 4.2.1 & 5 to 5.1.3

Lucinda Evans, Coordinator, MIP Items 5 to 5.1.3

Gemma Smith, Coordinator, COT Present for all items

Mohammed Towhasir, Administrator, TA Items 4.1.3 to 4.3.2

Iain Cannell, Administrator, TA Items 1 to 4.1.3 & 5 to 5.2.2

External assessment group representatives present

Mark Simmonds, Centre for Reviews and Dissemination and Centre for Health Economics -York, Items 1 to 4.2.1

Rob Hodgson, Centre for Reviews and Dissemination and Centre for Health Economics -York, Items 1 to 4.2.1

Nigel Armstrong, Kleijnen Systematic Reviews Ltd (KSR), Items 5 to 5.1.3

Manuela Joore, Kleijnen Systematic Reviews Ltd (KSR), Items 5 to 5.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Items 1 to 4.3.2

Professor Mhairi Copland, Professor of Translational Haematology, Clinical expert nominated by Royal College of Physicians and Royal College of Pathologists, Items 1 to 4.2.1

Gerard Graham Dickinson, Patient expert nominated by Chronic Myeloid Leukaemia Support Group, Items 1 to 4.2.1

David Fitzgerald, Patient expert nominated by Chronic Myeloid Leukaemia Support Group, Items 1 to 4.2.1

Professor Dragana Milojkovic, job title, Clinical expert nominated by Royal College of Physicians and Royal College of Pathologists, Items 1 to 4.2.1

Dr Sanjeev Patel, Innovative Medicines Fund Clinical lead, NHS England, Items 5 to 5.2.2

Jules Payne, Patient expert nominated by HEART UK – The Cholesterol Charity, Items 5 to 5.1.3

Dr Peter Penson, Patient expert nominated by HEART UK – The Cholesterol Charity, Items 5 to 5.1.3

NICE Observer present

Justin Whatling, Non-Executive Director, NICE, recently appointed appeal panel member, Items 1 to 4.2.1

## Minutes

### Introduction to the meeting

* 1. The chair Dr Richard Nicholas welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted committee member apologies from Dr Andrea Manca, Dr David Foreman, Dr Derek Ward, Professor Subhash Pokhrel, and Ugochi Nwulu.

### News and announcements

* 1. The chair announced that in attendance were new member to committee Iftab Akram and that NICE Non-Executive Director, Justin Whatling who is a recently appointed appeal panel member will be observing topic one - asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813].

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 6 April 2022.

### Appraisal of asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]

* 1. Part 2a – Closed session. The Committee for Medicinal Products for Human Use (CHMP) had not given a positive opinion on this technology, nor did it have a GB Marketing Authorisation, so all committee meeting discussions on this technology were confidential until this was received. Therefore, this discussion was held in a private part 2 session only, without the public in attendance.
		1. The chair welcomed the invited experts, external assessment group representatives, and company representatives from Novartis.
		2. The chair asked all committee members and experts, external assessment group representatives, NICE staff and NICE observer present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared financial interests as he has participated in an advisory panel for Pfizer, in an unrelated disease area. It was agreed that his declaration would not prevent Michael from participating in discussions on this appraisal.
* Committee member Dr Mudasar Mushtaq declared financial interests as he will be joining Novartis in June 2022.Dr Mushtaq confirmed that his new role is in relation to breast cancer, specifically kisqali, and he is not aware of any haematological cancers that he will be working with. It was agreed that his declaration would not prevent Dr Mushtaq from participating in discussions on this appraisal.
* Committee member Dr Richard Nicholas declared non-financial professional interests as he has carried out unpaid advisory work with Novartis in an unrelated disease area (MS). It was agreed that his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal
* Committee member & lead chair Professor Stephen O’Brien declared non-financial professional interests as CML has been his area of specialist interest for over 25 years and he has offered support/webinars (unpaid) to CML patient support groups for many years. He therefore asked the Vice Chair of TAC C, Dr Richard Nicholas, to chair this topic so that he might avoid unduly influencing the committee in its' deliberations.
* Nominated clinical expert Professor Mhairi Copland declared financial and non-financial interests as the University of Glasgow has received honoraria of £3100 on her behalf for advisory board attendance and speaker’s bureau presentations for Novartis. She also noted that her laboratory had received asciminib under a Material Transfer Agreement for preclinical studies of CML. It was agreed that her declaration would not prevent Professor Milojkovic from providing expert advice to the committee.
* Nominated clinical expert Professor Dragana Milojkovic declared financial interests as she has received speaker fees and research grants from BMS and Pfizer she is also a Sub-group Chair of the NCRI CML working party. It was agreed that her declaration would not prevent Professor Milojkovic from providing expert advice to the committee.
* No further interests were declared for this appraisal
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Nigel Langford, Stella O’Brien, and Professor Paul Tappenden.
	1. Part 2a – Closed session
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (company representatives, clinical and patient experts and external assessment group representatives were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10691>

### Appraisal of icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides [ID3831]

* 1. Part 1 – Open session
		1. The chair Professor Stephen O’Brien welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Amarin.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated clinical expert Dr Peter Penson declared direct and indirect financial interests as he has received honoraria and/or travel reimbursement for events sponsored by AKCEA, Amgen, AMRYT, Link Medical, Mylan, Napp, and Sanofi He also holds shares in AstraZeneca which he inherited and HEART UK has received funding from Bayer, Novartis, Daiichi Sankyo, Boehringer Ingelheim, Sanofi and Amgen. It was agreed that his declaration would not prevent Dr Penson from providing expert advice to the committee.
* Nominated patient expert Jules Payne declared indirect financial interests as HEART UK has received funding from Bayer, Novartis, Daiichi Sankyo, Boehringer Ingelheim, Sanofi and Amgen. It was agreed that her declaration would not prevent Jules from providing expert advice to the committee.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached through a vote by members.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10736>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Wednesday 1 June 2022 and will start promptly at 09.30.